Literature DB >> 17916991

Antiphospholipid syndrome and cancer.

Eyal Reinstein1, Yehuda Shoenfeld.   

Abstract

Thrombosis is a frequent complication of cancer that is a substantial cause of morbidity and mortality. The association of antiphospholipid antibodies (aPL) and cancer has been under investigation for several years. Recent findings suggest an increased prevalence of certain cancers in aPL-positive patients; thus, an intensive search for an occult malignancy is prompted in these patients. In addition, several studies reported on elevated levels of aPL in various malignancies; it seems, however, that aPL levels do not reflect their pathogenicity; therefore, their pathological significance in these subset of patients is still elusive. Continuing research on the association between the antiphospholipid syndrome/aPL and malignancies is important, given the potential impact on the understanding and treatment of both antiphospholipid syndrome and cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916991     DOI: 10.1007/s12016-007-0003-1

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  32 in total

1.  Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: a report of two cases.

Authors:  F Langer; B Eifrig; G Marx; A Stork; S Hegewisch-Becker; D K Hossfeld
Journal:  Ann Hematol       Date:  2002-11-09       Impact factor: 3.673

Review 2.  Pathophysiology of the antiphospholipid syndrome.

Authors:  P G de Groot; R H W M Derksen
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

3.  High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma.

Authors:  W Miesbach; I Scharrer; R A Asherson
Journal:  Clin Rheumatol       Date:  2006-05-24       Impact factor: 2.980

4.  Lupus-type coagulation inhibitor in hairy cell leukaemia and resolution with splenectomy.

Authors:  A S Duncombe; R G Dalton; G F Savidge
Journal:  Br J Haematol       Date:  1987-01       Impact factor: 6.998

Review 5.  Cancer and the prothrombotic state.

Authors:  Gregory Y H Lip; Bernard S P Chin; Andrew D Blann
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

6.  Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance.

Authors:  I S Lossos; V Bogomolski-Yahalom; Y Matzner
Journal:  Am J Hematol       Date:  1998-02       Impact factor: 10.047

Review 7.  Management of antiphospholipid antibody syndrome: a systematic review.

Authors:  Wendy Lim; Mark A Crowther; John W Eikelboom
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

Review 8.  Cancer and venous thromboembolism.

Authors:  Paolo Prandoni; Anna Falanga; Andrea Piccioli
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

Review 9.  The catastrophic antiphospholipid (Asherson's) syndrome and malignancies.

Authors:  W Miesbach; R A Asherson; R Cervera; Y Shoenfeld; J Gomez Puerta; S Bucciarelli; G Espinoza; J Font
Journal:  Autoimmun Rev       Date:  2006-07-21       Impact factor: 9.754

10.  Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy.

Authors:  E Zuckerman; E Toubi; T D Golan; T Rosenvald-Zuckerman; E Sabo; Z Shmuel; D Yeshurun
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more
  3 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

3.  Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study.

Authors:  D Dey; E Kenu; D A Isenberg
Journal:  Lupus       Date:  2013-07-15       Impact factor: 2.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.